Clinical Trial NU 12C06
- A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
- Principal Investigator
- Priya Kumthekar
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NU 12C06
- The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
- This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. Bevacizumab is a medication that blocks the growth of new blood vessels. In order for tumors to grow, they need to have a blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. It is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Bevacizumab is approved by the Food and Drug Administration (FDA) for the treatment of certain types of cancer including lung cancer, kidney cancer and a type of brain cancer called glioblastoma multiforme. However, bevacizumab is considered investigational in this study because it is not approved by the FDA for the treatment of solid tumor cancers that have spread to the brain.
Some of the eligibility criteria include:
- Participants must have a solid tumor cancer that has spread to the brain.
- Participants must have gotten worse after having prior whole brain radiation therapy (WBRT).
- Participants must be 18 or older.
- Description of Treatment
- Participants will receive the study drug in periods called cycles; each cycle will be 28 days long (about 4 weeks). The study drug is given as an intravenous (IV) infusion through a vein in the arm. Participants will receive the study drug treatments on or around Days 1 and 15 of each cycle (or about every 2 weeks). Participants may continue to receive drug until their disease gets worse or they have unacceptable side effects.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
- Breast: Female
- Breast: Male
- Endocrine: Thyroid
- Endocrine: Other endocrine system
- Gastrointestinal: Anus
- Gastrointestinal: Colon
- Gastrointestinal: Esophagus
- Gastrointestinal: Stomach
- Gastrointestinal: Liver
- Gastrointestinal: Pancreas
- Gastrointestinal: Small intestine
- Gastrointestinal: Other digestive organ
- Genitourinary: Urinary bladder
- Genitourinary: Kidney
- Genitourinary: Other urinary
- Genitourinary: Prostate
- Genitourinary: Other male genital
- Lung: Other respiratory, intrathoracic organs
- Skin: Melanoma
- Skin: Kaposi's Sarcoma
- Skin: Other skin
- Soft Tissue
- Bones and joints
- Eye and orbit
- Gastrointestinal: Rectum
- Gynecological: Cervix
- Gynecological: Corpus/Uterus
- Gynecological: Ovarian
- Gynecological: Other female genital
- Head and neck: Buccal cavity/pharynx
- Head and neck: Esophagus
- Head and neck: Larynx
- Head and neck: Thyroid
Other Clinical Trials by Priya Kumthekar
- A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
- A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
last updated: 09-Dec-16 01:49 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.